Mode
Text Size
Log in / Sign up
Phase 3 N=569 Randomized Double-blind Treatment

A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)

Depressive Disorder, Major

Enrolled (actual)
569
Serious AEs
0.9%
Results posted
May 2013
Primary outcome: Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal — -13.9; -14.4; -12.9 Scores on a scale — p=0.853

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
323U66 SR 150 mg tablet (Drug); 323U66 SR 150 mg placebo tablet (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Aug 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8/Withdrawal
-13.9; -14.4; -12.9 0.853
SECONDARY
Change From Baseline in the MADRS Total Score at Weeks 1, 2, 4, and 6
-3.4; -2.9; -2.7; -6.2; -5.0; -5.0
SECONDARY
Change From Baseline in the MADRS Individual Item Scores at Weeks 1, 2, 4, 6, and 8
-0.5; -0.3; -0.3; -0.7; -0.5; -0.6
SECONDARY
Number of MADRS Responders at Week 8
86; 98; 82
SECONDARY
Number of MADRS Remitters at Week 8
53; 60; 56
SECONDARY
Number of Clinical Global Impression-Global Improvement (CGI-GI) Responders at Week 8
100; 103; 98
SECONDARY
Change From Baseline in the Clinical Global Impression-Severity of Illness (CGI-SI) Scores at Weeks 1, 2, 4, 6, and 8
-0.2; -0.1; -0.1; -0.3; -0.3; -0.2
SECONDARY
Change From Baseline in the Inventory of Depressive Symptomatology-Self Report (IDS-SR) Total Score at Weeks 1, 2, 4, 6, and 8
-4.8; -4.2; -3.9; -6.9; -6.7; -5.8
SECONDARY
Change From Baseline in the IDS-SR Subscores for Energy, Pleasure, and Interest at Weeks 1, 2, 4, 6, and 8
-1.1; -0.9; -0.9; -1.3; -1.2; -1.3

Summary

This is a multi-center, placebo-controlled, randomized, double-blind, parallel-comparison study to confirm the efficacy of 323U66 Sustained Release (SR) orally administered to patients with MDD (Major Depressive Disorder) at doses level of 150 mg/day and 300 mg/day for 8 weeks based on the decrease in MADRS (Montgomery-Asberg Depression Rating Scale) total score, and to evaluate the safety based on adverse events, clinical laboratory tests and vital signs.

Eligibility Criteria

Inclusion Criteria

[At the start time of the run-in phase]

  • Subject must have a primary diagnosis of major depressive disorder as classified by the DSM-IV-TR criteria as below (however, to exclude those accompanied by comorbid psychiatric disorders), and be showing currently a symptom of depression or depressive status: Major depressive disorder, single episode (296.2x); Major depressive disorder, recurrent (296.3x).
  • Subject must have a total score of >=20 on the IVRS HAM-D (17 items).
  • Subject must have a total score of >=25 on the IDS-SR.
  • Subject must have a score of >=1 on 4 out 5 items on the 5-item subscale of the IDS-SR (Item 19, 20, 21, 22 and 30), and a total score of >=7 on the 5-item subscale of the IDS-SR.
  • Subject must have a CGI-SI score of >=4 (i.e., Moderately ill or much worse).
  • Subject must have the current depressive episode's duration of >=8 weeks but 35% of direct bilirubin with a value >=1.5 times of the upper limit of normal range of total bilirubin regards eligible).
  • Subject must read and write at a level sufficient to provide written informed consent prior to study participation and complete study-related materials. If subject is =20 of the IVRS-based HAM-D (17 items).
  • Subject whose IVRS HAM-D (17 items) total score has not been increased or decreased by >25% during the run-in phase.
  • Subject must have a total score of >=25 on the IDS-SR.
  • Subject must have a score of >=1 on 4 out 5 items on the 5-item subscale of the IDS-SR (Item 19, 20, 21, 22 and 30), and a total score of >=7 on the 5-item subscale of the IDS-SR.
  • Subject must have a CGI-SI score of >=4 (i.e., Moderately ill or much worse).

Exclusion Criteria

[At the start time of Run-in phase (Visit 1)]

  • Subject has predispositions to seizure: who currently has or has a past history of seizure or seizure disorder, more than a single febrile seizure in infancy, cerebral tumour, or head / brain injury (traumatic); who has a family history of idiopathic seizure; who is diabetic patient with treating by oral hypoglycaemics or insulin; who uses drugs lowering the threshold of seizure.
  • Subject has a history or current diagnosis of anorexia nervosa (DSM-IV-TR 307.1) or bulimia (DSM-IV-TR 307.51).
  • Subject has a primary DSM-IV diagnosis of, or received treatment for, panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), or acute stress disorder within 12 months before the start time of Run-in phase.
  • Subject has a DSM-IV diagnosis of schizophrenia, or other psychotic disorder(s) including bipolar disorder.
  • Subject has a history of or currently has manic episode(s).
  • Subject has any other DSM-IV axis II diagnosis that would suggest non-responsiveness to pharmacotherapy or non-compliance with the protocol (e.g., antisocial, borderline disorder or narcissistic personality disorder).
  • Subject starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) or a cognitive behaviour therapy within 12 weeks before start time of the run-in phase.
  • Subject received electroconvulsive therapy (ECT) within 24 weeks before start time of the run-in phase.
  • Subject took MAO inhibitors (selegiline hydrochloride) within 2 weeks before start time of the run-in phase.
  • Subject who has undergone treatment with a depot neuroleptic in the past.
  • Subject has systolic blood pressure of >=160 mmHg or diastolic pressure of >=100 mmHg.
  • Subject 1) is possibly pregnant, 2) is pregnant, lactating, or 3) does not agree to use contraceptive method(s) specified in the protocol to avoid pregnancy during the study (females only). Or subject wants to become pregnant during the study (females only).
  • Subject has a history of alcohol / substance abuse or dependence within 12 months before start time of the run-in phase and/or has a positive result in a urine test for illicit drug use at start time of the run-in phase.
  • Subject, who in the opinion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01138007). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search